Alfredo Addeo

33PUBLICATIONS
239CO-AUTHORS
Molecular targetsPacific Peoples design practice and managementPredictive and prognostic markersInnate immunityHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|Jan 06, 2026
Efficacy of Immune Checkpoint Inhibitors and Oncoviruses in Solid Tumors.

Hiba Mechahougui, Léna Royston, Catia Vieira Gomes

|Dec 11, 2025
[Involving Patient Partners: Platforms and Strategies in French-Speaking Switzerland].

Hélène Chanvrier, Alfredo Addeo, Cindy Allenbach

|Aug 27, 2025
First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC.

Federica Pecci, Hui Li, Alessandro Di Federico

|Jul 17, 2025
Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management.

Maxime Borgeaud, Timothée Olivier, Jair Bar

|Feb 15, 2025
Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back.

Annapaola Mariniello, Maxime Borgeaud, Marc Weiner

|Nov 22, 2024
Safety and Efficacy of Osimertinib in Patients With Non-Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis.

Jonathan N Priantti, Yu Fujiwara, Francisco Cezar Aquino de Moraes

Pageof 6

Frequent Collaborators

5 joint publications

Giuseppe Luigi Banna

4 joint publications

Alessio Cortellini

3 joint publications

Alex Friedlaender

3 joint publications

Vivek Subbiah